JDRR — F3 Platform Biologics Income Statement
0.000.00%
Last trade - 00:00HealthcareMicro Cap
Annual income statement for F3 Platform Biologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Total Operating Expenses | 0.259 | 1.93 | 0.624 |
| Operating Profit | -0.259 | -1.93 | -0.624 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | 0.023 | -2.21 | -0.927 |
| Net Income After Taxes | 0.023 | -2.21 | -0.927 |
| Net Income Before Extraordinary Items | |||
| Net Income | 0.023 | -2.21 | -0.927 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | 0.023 | -2.21 | -0.927 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | 0 | -0.032 | -0.013 |